CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBC

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05375903
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:38.424702+00:00
Published At: 2026-01-14T00:00:00+00:00
Record Updated At: 2026-01-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non-muscle Invasive Bladder Cancer", "NMIBC", "Carcinoma in Situ of Bladder", "Bladder Cancer", "Urothelial Carcinoma Bladder", "Urothelial Carcinoma Recurrent"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-14"
protocolSection.identificationModule.nctId: "NCT05375903"
protocolSection.identificationModule.officialTitle: "A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBC"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.